Progyny, Inc. $PGNY Stock Holdings Lifted by Ieq Capital LLC

Key Points

• Ieq Capital LLC significantly increased its holdings in Progyny, Inc. by 218.8%, acquiring an additional 54,217 shares during the first quarter, bringing its total ownership to approximately 78,993 shares worth $1,765,000.
• Institutional investors own 94.93% of Progyny's stock, indicating strong support from major financial players.
• Progyny reported earnings of $0.19 per share, missing analysts' estimates, but achieved revenue of $332.87 million, surpassing expectations with a 9.5% year-over-year increase.

Ieq Capital LLC raised its holdings in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 218.8% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 78,993 shares of the company's stock after acquiring an additional 54,217 shares during the period. Ieq Capital LLC owned approximately 0.09% of Progyny worth $1,765,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. BI Asset Management Fondsmaeglerselskab A S bought a new stake in Progyny during the 1st quarter valued at $44,000. Brooklyn Investment Group raised its stake in Progyny by 5,216.4% during the 1st quarter. Brooklyn Investment Group now owns 3,243 shares of the company's stock valued at $72,000 after acquiring an additional 3,182 shares in the last quarter. GAMMA Investing LLC raised its stake in Progyny by 233.9% during the 1st quarter. GAMMA Investing LLC now owns 5,379 shares of the company's stock valued at $120,000 after acquiring an additional 3,768 shares in the last quarter. AlphaQuest LLC raised its stake in Progyny by 57.9% during the 1st quarter. AlphaQuest LLC now owns 5,668 shares of the company's stock valued at $127,000 after acquiring an additional 2,079 shares in the last quarter. Finally, Sei Investments Co. bought a new stake in Progyny during the 1st quarter valued at $228,000. Institutional investors own 94.93% of the company's stock.

Progyny Trading Down 4.3%

Shares of NASDAQ PGNY traded down $1.01 during mid-day trading on Friday, reaching $22.55. The company had a trading volume of 978,886 shares, compared to its average volume of 1,029,759. The stock has a market cap of $1.94 billion, a PE ratio of 38.22, a P/E/G ratio of 1.84 and a beta of 1.33. The company has a 50-day moving average price of $22.94 and a two-hundred day moving average price of $22.23. Progyny, Inc. has a 1-year low of $13.39 and a 1-year high of $26.76.

Progyny (NASDAQ:PGNY - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $0.19 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.42 by ($0.23). Progyny had a return on equity of 10.69% and a net margin of 4.28%.The company had revenue of $332.87 million during the quarter, compared to analyst estimates of $315.70 million. During the same quarter in the previous year, the firm earned $0.17 earnings per share. The business's revenue was up 9.5% compared to the same quarter last year. Progyny has set its Q3 2025 guidance at EPS. FY 2025 guidance at 1.700-1.780 EPS. On average, research analysts expect that Progyny, Inc. will post 0.6 EPS for the current year.

Insider Activity

In other news, Director Kevin K. Gordon sold 2,500 shares of Progyny stock in a transaction on Monday, August 11th. The stock was sold at an average price of $22.04, for a total transaction of $55,100.00. Following the transaction, the director owned 12,501 shares in the company, valued at approximately $275,522.04. The trade was a 16.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Cheryl Scott sold 2,675 shares of Progyny stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $22.07, for a total value of $59,037.25. Following the transaction, the director owned 14,112 shares in the company, valued at $311,451.84. This represents a 15.93% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 10,570 shares of company stock worth $238,348. 9.40% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts have recently commented on PGNY shares. Leerink Partners raised Progyny from a "market perform" rating to an "outperform" rating and set a $28.00 price objective on the stock in a research note on Tuesday, July 8th. Raymond James Financial set a $28.00 price objective on Progyny in a research note on Friday, August 8th. Leerink Partnrs raised Progyny from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, July 8th. Cantor Fitzgerald reissued an "overweight" rating and issued a $28.00 price objective (up previously from $26.00) on shares of Progyny in a research note on Friday, August 8th. Finally, Truist Financial boosted their price objective on Progyny from $24.00 to $27.00 and gave the stock a "hold" rating in a research note on Thursday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $25.30.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.